230 related articles for article (PubMed ID: 20458068)
1. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.
Lashley D; Palace J; Jayawant S; Robb S; Beeson D
Neurology; 2010 May; 74(19):1517-23. PubMed ID: 20458068
[TBL] [Abstract][Full Text] [Related]
2. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation.
Lorenzoni PJ; Scola RH; Kay CS; Filla L; Miranda AP; Pinheiro JM; Chaouch A; Lochmüller H; Werneck LC
J Neurol Sci; 2013 Aug; 331(1-2):155-7. PubMed ID: 23790237
[TBL] [Abstract][Full Text] [Related]
3. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations.
Burke G; Hiscock A; Klein A; Niks EH; Main M; Manzur AY; Ng J; de Vile C; Muntoni F; Beeson D; Robb S
Neuromuscul Disord; 2013 Feb; 23(2):170-5. PubMed ID: 23219351
[TBL] [Abstract][Full Text] [Related]
4. Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.
Rodríguez Cruz PM; Palace J; Ramjattan H; Jayawant S; Robb SA; Beeson D
Neurology; 2015 Sep; 85(12):1043-7. PubMed ID: 26296515
[TBL] [Abstract][Full Text] [Related]
5. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children.
Tsao CY
Pediatr Neurol; 2016 Jan; 54():85-7. PubMed ID: 26552645
[TBL] [Abstract][Full Text] [Related]
6. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations.
Schara U; Barisic N; Deschauer M; Lindberg C; Straub V; Strigl-Pill N; Wendt M; Abicht A; Müller JS; Lochmüller H
Neuromuscul Disord; 2009 Dec; 19(12):828-32. PubMed ID: 19837590
[TBL] [Abstract][Full Text] [Related]
7. DOK7 congenital myasthenic syndrome.
Palace J
Ann N Y Acad Sci; 2012 Dec; 1275():49-53. PubMed ID: 23278577
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of the DOK7 neuromuscular junction synaptopathy.
Palace J; Lashley D; Newsom-Davis J; Cossins J; Maxwell S; Kennett R; Jayawant S; Yamanashi Y; Beeson D
Brain; 2007 Jun; 130(Pt 6):1507-15. PubMed ID: 17452375
[TBL] [Abstract][Full Text] [Related]
9. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes.
Müller JS; Herczegfalvi A; Vilchez JJ; Colomer J; Bachinski LL; Mihaylova V; Santos M; Schara U; Deschauer M; Shevell M; Poulin C; Dias A; Soudo A; Hietala M; Aärimaa T; Krahe R; Karcagi V; Huebner A; Beeson D; Abicht A; Lochmüller H
Brain; 2007 Jun; 130(Pt 6):1497-506. PubMed ID: 17439981
[TBL] [Abstract][Full Text] [Related]
10. DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine.
Santos M; Cruz S; Peres J; Santos L; Tavares P; Basto JP; Salgado V; Valverde AH
Neuromuscul Disord; 2018 Mar; 28(3):278-282. PubMed ID: 29395672
[TBL] [Abstract][Full Text] [Related]
11. DOK7 limb-girdle myasthenic syndrome mimicking congenital muscular dystrophy.
Mahjneh I; Lochmüller H; Muntoni F; Abicht A
Neuromuscul Disord; 2013 Jan; 23(1):36-42. PubMed ID: 22884442
[TBL] [Abstract][Full Text] [Related]
12. Dok-7/MuSK signaling and a congenital myasthenic syndrome.
Yamanashi Y; Higuch O; Beeson D
Acta Myol; 2008 Jul; 27(1):25-9. PubMed ID: 19108574
[TBL] [Abstract][Full Text] [Related]
13. Intra-familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations.
Yeung WL; Lam CW; Ng PC
Dev Med Child Neurol; 2010 Oct; 52(10):e243-4. PubMed ID: 20370815
[No Abstract] [Full Text] [Related]
14. [Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy--The French National Congenital Myasthenic Syndrome Network experience].
Eymard B; Stojkovic T; Sternberg D; Richard P; Nicole S; Fournier E; Béhin A; Laforêt P; Servais L; Romero N; Fardeau M; Hantaï D;
Rev Neurol (Paris); 2013 Feb; 169 Suppl 1():S45-55. PubMed ID: 23452772
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes.
Mihaylova V; Müller JS; Vilchez JJ; Salih MA; Kabiraj MM; D'Amico A; Bertini E; Wölfle J; Schreiner F; Kurlemann G; Rasic VM; Siskova D; Colomer J; Herczegfalvi A; Fabriciova K; Weschke B; Scola R; Hoellen F; Schara U; Abicht A; Lochmüller H
Brain; 2008 Mar; 131(Pt 3):747-59. PubMed ID: 18180250
[TBL] [Abstract][Full Text] [Related]
16. Variable phenotypes associated with mutations in DOK7.
Anderson JA; Ng JJ; Bowe C; McDonald C; Richman DP; Wollmann RL; Maselli RA
Muscle Nerve; 2008 Apr; 37(4):448-56. PubMed ID: 18161030
[TBL] [Abstract][Full Text] [Related]
17. Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7.
Ben Ammar A; Petit F; Alexandri N; Gaudon K; Bauché S; Rouche A; Gras D; Fournier E; Koenig J; Stojkovic T; Lacour A; Petiot P; Zagnoli F; Viollet L; Pellegrini N; Orlikowski D; Lazaro L; Ferrer X; Stoltenburg G; Paturneau-Jouas M; Hentati F; Fardeau M; Sternberg D; Hantaï D; Richard P; Eymard B
J Neurol; 2010 May; 257(5):754-66. PubMed ID: 20012313
[TBL] [Abstract][Full Text] [Related]
18. Congenital myasthenic syndrome due to DOK7 mutation in a cohort of patients with 'unexplained' limb-girdle muscular weakness.
Lorenzoni PJ; Kay CSK; Arndt RC; Hrysay NMC; Ducci RD; Fustes OHJ; Töpf A; Lochmüller H; Werneck LC; Scola RH
J Clin Neurosci; 2020 May; 75():195-198. PubMed ID: 32238315
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome.
Witting N; Vissing J
JAMA Neurol; 2014 Mar; 71(3):350-4. PubMed ID: 24425145
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic Differences in 2 Unrelated Cases Carrying Identical DOK7 Mutations.
Bissay V; Maselli RA
J Clin Neuromuscul Dis; 2019 Sep; 21(1):30-34. PubMed ID: 31453852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
